PsiThera Secures $47.5M Series A Funding

PsiThera, a biotechnology company dedicated to transforming the treatment of immune and inflammatory diseases, has secured $47,500,000 in new funding from investors.

The company specializes in harnessing biologically relevant protein states and advanced computational intelligence to create novel oral drugs for conditions that have historically depended on injectable therapies.

PsiThera's integrated approach combines expertise in biophysics, sophisticated computational modeling, and mechanistic biology, empowering its expert drug hunters to identify new therapeutic opportunities and develop optimized drug candidates.

This substantial capital infusion marks a pivotal moment for PsiThera, signaling strong investor confidence in its innovative drug discovery platform and its potential to address significant unmet medical needs.

The newly raised funds are specifically allocated to accelerate the advancement of the company’s rapidly progressing pipeline.

This pipeline primarily targets high-value targets, commencing with the Tumor Necrosis Factor (TNF) superfamily, with the aim of delivering more convenient and patient-friendly oral treatment options.

Furthermore, the investment will significantly bolster PsiThera’s proprietary technological infrastructure and expand its cutting-edge drug discovery and development capabilities.

By strengthening its research and development operations, the company plans to efficiently progress its lead pipeline candidates towards critical clinical development stages.

PsiThera is strategically poised for robust growth, with a clear vision to introduce its innovative oral therapeutics to patients and broaden its impact within the dynamic field of immunology.